A Phase 3 interventional study of Sacituzumab Govitecan-hziy and Eribulin in Metastatic Breast Cancer, sponsored by Gilead Sciences. Completed at 113 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing sacituzumab govitecan in Breast Neoplasms — 16 open to participants now, 24 under way, 4 of them phase 3. sacituzumab govitecan · Breast Neoplasms.
Among the 27 studies testing sacituzumab govitecan in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2019, is one of 6 in phase 3, and was the 4th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →16 of the 27 studies testing sacituzumab govitecan in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Nathalie Levasseur · Sites in Canada
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
British Columbia Cancer Agency · Sites in Canada
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Women only
Reshma L. Mahtani, D.O. · Sites in United States
Ages 18+
By country, each count listing its studies:
sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, sacituzumab govitecan is the treatment under test here. Read study by study →
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 6
First in 2012; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 543 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 75 across the 27 interventional studies. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 27 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 9 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
14 of the studies testing sacituzumab govitecan in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT04434040Dana-Farber Cancer InstituteAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | 2026-12-30 |
| NCT05675579M.D. Anderson Cancer CenterA Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | 2026-12-31 |
| NCT07359404YING FANSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 27 studies testing sacituzumab govitecan in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess and compare the efficacy and safety of sacituzumab govitecan-hzi versus treatment of physician's choice (TPC) in participants with hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC).
Key Inclusion Criteria:
to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for metastatic disease:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive sacituzumab govitecan-hziy 10 mg/kg via intravenous (IV) injection administered on Day 1 and Day 8 of a 21-day cycle.
Drug: Sacituzumab Govitecan-hziy
Participants will receive TPC determined prior to randomization from one of the following single-agent treatment: Dosing per National Comprehensive Cancer Network (NCCN) guidelines (with dose modifications for if toxic) * Eribulin: 1.4 mg/m\^2 for North American sites, 1.23 mg/m\^2 for European sites) via IV on Days 1 and 8 of a 21-day cycle * Capecitabine: 1000-1250 mg/m\^2 orally twice daily for 2 weeks followed by a 1-week rest period given as a 21-day cycle * Gemcitabine: 800-1200 mg/m\^2 via IV on Days 1, 8, and 15 of each 28-day cycle or per institution * Vinorelbine: 25 mg/m\^2 via IV on Day 1 weekly cycle per institution
Drug: Eribulin · Drug: Capecitabine · Drug: Gemcitabine · Drug: Vinorelbine
Administered intravenously
Also known as: IMMU-132, GS-0132
Administered intravenously per NCCN guidelines
Administered orally per NCCN guidelines
Administered intravenously per NCCN guidelines
Administered intravenously per NCCN guidelines
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment
PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurred first) according to BICR using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Disease progression was defined as an increase of greater than 20% in the sum of the longest diameter (LD) of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.
Time frame: Up to 42.8 months
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death from any cause. OS was estimated using Kaplan-Meier estimate. Participants without documentation of death were censored on the date they were last known to be alive.
Time frame: Up to 42.8 months
Objective Response Rate (ORR) by BICR and Local Investigator Review (LIR) Assessment
ORR was defined as the percentage of participants who had the best overall response of either complete response (CR) or partial response (PR) that was confirmed at 4 weeks or later after initial response by BICR and LIR using RECIST 1.1. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.
Time frame: Up to 42.8 months
Duration of Response (DOR) by BICR and LIR Assessment
DOR was defined as the time from the date a response of CR or PR was first documented until the date of the first documentation of disease progression or date of death (whichever occurred first). DOR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. DOR was estimated using Kaplan-Meier estimate.
Time frame: Up to 42.8 months
Clinical Benefit Rate (CBR) by BICR and LIR Assessment
CBR was defined as the percentage of participants with the best overall response of CR, PR, or durable stable disease (duration of SD ≥ 6 months after randomization). CBR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. PD: Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions.
Time frame: Up to 42.8 months
PFS by LIR Assessment
PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurred first) according to LIR using RECIST 1.1. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.
Time frame: Up to 42.8 months
Time to Deterioration (TTD) of Global Health Status/Quality of Life (QoL) Scale as Measured by European Organization for Research and Treatment of Cancer Quality of Life for Cancer Patients, Core Questionnaire Version 3.0 (EORTC QLQ-C30)
TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the global health status/QoL scale.The EORTC QLQ-C30 is a 30-item questionnaire to assess QoL of cancer patients. It has 5 functional scales(physical,role,emotional,cognitive, social)1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). Participant responses to global health status,'How would you rate your overall health during the past week?' (Item 29)and the QoL 'How would you rate your overall quality of life during the past week?'(Item 30)questions were scored on 7-point scale (1=very poor; 7=excellent). All scales and single-item measures range in score from 0 to 100. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100. Higher scores for GHS show a better level of functioning.
Time frame: Up to 37.8 months
TTD of Pain Score as Measured by EORTC QLQ-C30
TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the pain score.The EORTC QLQ-C30 is a questionnaire to assess quality of life, it is composed of 30 questions(items) resulting in 5 functional scales(physical, role, emotional, cognitive, social),1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Participant responses to 2 questions about pain, 'Have you had pain' and 'Did pain interfere with your daily activities' were scored on 4-point scale (1=not at all;4=very much). Summed raw scores were standardized by linear transformation so that scores ranges from 0 to 100. Higher scores on the symptom scales indicate a higher level of symptoms (i.e. a worse state of the participant).
Time frame: Up to 37.8 months
TTD of Fatigue Score as Measured by EORTC QLQ-C30
TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the fatigue score.The EORTC QLQ-C30 is a questionnaire to assess quality of life, it is composed of 30 questions(items) resulting in 5 functional scales(physical, role, emotional, cognitive, social),1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties).All of the scales and single-item measures range in score from 0 to 100.Participant responses to 3 questions about fatigue 'Did you need to rest', 'Have you felt weak' and 'Were you tired' were scored on a 4-point scale (1=not at all;4=very much).Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100. Higher scores on the symptom scales indicate a higher level of symptoms (i.e. a worse state of the participant).
Time frame: Up to 37.8 months
Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a subject administered a medicinal product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of the study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.
Time frame: Up to 43.4 months
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (TESAEs)
Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above
Time frame: Up to 43.4 months
Percentage of Participants Who Experienced the Worst Laboratory Abnormalities Grade 3 or 4 Post-Baseline
Blood samples were collected for hematology, serum chemistry, and the laboratory abnormalities were assessed. A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days.The most severe graded abnormality observed post-baseline for each graded test was counted for each participant. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) covering grades 0-5 (0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death). The percentage of participants with worst postbaseline grades 3 or 4 are reported.
Time frame: Up to 43.4 months
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) - Shift From Baseline Value to Best Value During Treatment
ECOG performance status (PS) measured on-therapy assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease performance without restriction;1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature;2=Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours;3=Capable of only limited self-care;confined to bed or chair more than 50% of waking hours;4=Completely disabled; cannot carry on any self-care; totally confined to bed or chair;5=Dead. Lower score indicated good performance status. Percentage of participants with Baseline ECOG PS score and corresponding changes to the best values post-baseline have been reported.
Time frame: Up to 43.4 months
Participants were enrolled at study sites in Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, the United Kingdom, and the United States.
| Milestone | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| Started | 272 | 271 |
| Received at least 1 dose of study drug | 268 | 249 |
| Completed | 0 | 0 |
| Not completed | 272 | 271 |
| Withdrew: Death | 220 | 192 |
| Withdrew: Informed consent withdrawn | 13 | 40 |
| Withdrew: Sponsor request | 30 | 23 |
| Withdrew: Reason not specified | 5 | 7 |
| Withdrew: Lost to follow-up | 4 | 7 |
| Withdrew: Covid19 | 0 | 2 |
PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurred first) according to BICR using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Disease progression was defined as an increase of greater than 20% in the sum of the longest diameter (LD) of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.
| months | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment | 5.5 (4.2 to 6.9) | 4.0 (3.0 to 4.4) |
OS was defined as the time from the date of randomization to the date of death from any cause. OS was estimated using Kaplan-Meier estimate. Participants without documentation of death were censored on the date they were last known to be alive.
| months | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| Overall Survival (OS) | 14.5 (13.0 to 16.0) | 11.2 (10.2 to 12.6) |
ORR was defined as the percentage of participants who had the best overall response of either complete response (CR) or partial response (PR) that was confirmed at 4 weeks or later after initial response by BICR and LIR using RECIST 1.1. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.
| percentage of participants | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| ORR by BICR Assessment | 21.3 (16.6 to 26.7) | 14.0 (10.1 to 18.7) |
| ORR by LIR Assessment | 16.5 (12.3 to 21.5) | 9.2 (6.1 to 13.3) |
DOR was defined as the time from the date a response of CR or PR was first documented until the date of the first documentation of disease progression or date of death (whichever occurred first). DOR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. DOR was estimated using Kaplan-Meier estimate.
| months | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| DOR by BICR Assessment | 8.1 (6.7 to 8.9) | 5.6 (3.8 to 7.9) |
| DOR by LIR Assessment | 7.0 (5.6 to 8.9) | 4.3 (4.2 to 6.1) |
CBR was defined as the percentage of participants with the best overall response of CR, PR, or durable stable disease (duration of SD ≥ 6 months after randomization). CBR was analyzed based on both BICR and LIR assessments. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. PD: Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions.
| percentage of participants | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| CBR by BICR Assessment | 33.8 (28.2 to 39.8) | 22.1 (17.3 to 27.6) |
| CBR by LIR Assessment | 32.4 (26.8 to 38.3) | 21.0 (16.3 to 26.4) |
PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurred first) according to LIR using RECIST 1.1. Disease progression was defined as an increase of greater than 20% in the sum of the LD of target lesions and a 5 mm absolute increase, taking as a reference the smallest sum LD recorded since the baseline assessment or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.
| months | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| PFS by LIR Assessment | 4.3 (3.8 to 5.4) | 3.1 (2.7 to 4.0) |
TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the global health status/QoL scale.The EORTC QLQ-C30 is a 30-item questionnaire to assess QoL of cancer patients. It has 5 functional scales(physical,role,emotional,cognitive, social)1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). Participant responses to global health status,'How would you rate your overall health during the past week?' (Item 29)and the QoL 'How would you rate your overall quality of life during the past week?'(Item 30)questions were scored on 7-point scale (1=very poor; 7=excellent). All scales and single-item measures range in score from 0 to 100. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100. Higher scores for GHS show a better level of functioning.
| months | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| Time to Deterioration (TTD) of Global Health Status/Quality of Life (QoL) Scale as Measured by European Organization for Research and Treatment of Cancer Quality of Life for Cancer Patients, Core Questionnaire Version 3.0 (EORTC QLQ-C30) | 4.3 (3.1 to 5.7) | 3.0 (2.2 to 3.9) |
TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the pain score.The EORTC QLQ-C30 is a questionnaire to assess quality of life, it is composed of 30 questions(items) resulting in 5 functional scales(physical, role, emotional, cognitive, social),1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Participant responses to 2 questions about pain, 'Have you had pain' and 'Did pain interfere with your daily activities' were scored on 4-point scale (1=not at all;4=very much). Summed raw scores were standardized by linear transformation so that scores ranges from 0 to 100. Higher scores on the symptom scales indicate a higher level of symptoms (i.e. a worse state of the participant).
| months | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| TTD of Pain Score as Measured by EORTC QLQ-C30 | 3.8 (2.8 to 5.0) | 3.5 (2.8 to 5.0) |
TTD was defined as the time from randomization to the first date a subject achieves 10-point deterioration from baseline in the fatigue score.The EORTC QLQ-C30 is a questionnaire to assess quality of life, it is composed of 30 questions(items) resulting in 5 functional scales(physical, role, emotional, cognitive, social),1 global health status scale,3 symptom scales (fatigue, nausea and vomiting, pain),and 6 single items(dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties).All of the scales and single-item measures range in score from 0 to 100.Participant responses to 3 questions about fatigue 'Did you need to rest', 'Have you felt weak' and 'Were you tired' were scored on a 4-point scale (1=not at all;4=very much).Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100. Higher scores on the symptom scales indicate a higher level of symptoms (i.e. a worse state of the participant).
| months | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| TTD of Fatigue Score as Measured by EORTC QLQ-C30 | 2.2 (1.6 to 2.8) | 1.4 (1.1 to 1.9) |
An AE was defined as any untoward medical occurrence in a subject administered a medicinal product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of the study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.
| percentage of participants | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) | 100.0 | 96.0 |
Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above
| percentage of participants | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (TESAEs) | 27.6 | 19.3 |
Blood samples were collected for hematology, serum chemistry, and the laboratory abnormalities were assessed. A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days.The most severe graded abnormality observed post-baseline for each graded test was counted for each participant. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) covering grades 0-5 (0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death). The percentage of participants with worst postbaseline grades 3 or 4 are reported.
| percentage of participants | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| Alanine Aminotransferase Increased | 1.1 | 2.1 |
| Hypoalbuminemia | 0 | 0.4 |
| Alkaline Phosphatase Increased | 0 | 0.8 |
| Aspartate Aminotransferase Increased | 1.5 | 1.3 |
| Bilirubin Increased | 2.3 | 0.8 |
| Creatinine Increased | 0.4 | 1.7 |
| Creatinine Clearance Decreased | 2.3 | 1.3 |
| Hypoglycemia | 1.1 | 0.8 |
| Hypermagnesemia | 0.4 | 0 |
| Hypomagnesemia | 0.8 | 0 |
| Hyperkalemia | 1.9 | 0 |
| Hypokalemia | 4.2 | 0.4 |
| Hyponatremia | 0.8 | 0.4 |
| Anemia | 7.5 | 5.0 |
| Hemoglobin Increased | 1.1 | 0 |
| Leukocytes Decreased | 38.9 | 25.7 |
| Leukocytosis | 0.4 | 0.4 |
| Lymphocytes Decreased | 21.5 | 13.7 |
| Lymphocytes Increased | 1.9 | 2.1 |
| Neutrophils Decreased | 53.2 | 40.2 |
| Platelets Decreased | 1.9 | 3.7 |
ECOG performance status (PS) measured on-therapy assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease performance without restriction;1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature;2=Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours;3=Capable of only limited self-care;confined to bed or chair more than 50% of waking hours;4=Completely disabled; cannot carry on any self-care; totally confined to bed or chair;5=Dead. Lower score indicated good performance status. Percentage of participants with Baseline ECOG PS score and corresponding changes to the best values post-baseline have been reported.
| percentage of participants | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| Baseline ECOG 0, During Treatment ECOG 0 | 34.9 | 38.7 |
| Baseline ECOG 0, During Treatment ECOG 1 | 7.8 | 8.9 |
| Baseline ECOG 0, During Treatment ECOG 2 | 0 | 0.4 |
| Baseline ECOG 1, During Treatment ECOG 0 | 19.4 | 11.5 |
| Baseline ECOG 1, During Treatment ECOG 1 | 36.4 | 38.3 |
| Baseline ECOG 1, During Treatment ECOG 2 | 1.6 | 2.1 |
Collected over Adverse Events and All-Cause Mortality: Up to 43.4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sacituzumab Govitecan | 234/272 (86%) | 74/268 (27.6%) | 264/268 (98.5%) |
| Treatment of Physician's Choice (TPC) | 238/271 (87.8%) | 48/249 (19.3%) | 234/249 (94%) |
| Event | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 13/268 | 1/249 |
| Febrile neutropeniaBlood and lymphatic system disorders | 11/268 | 10/249 |
| NeutropeniaBlood and lymphatic system disorders | 8/268 | 2/249 |
| Abdominal painGastrointestinal disorders | 6/268 | 0/249 |
| NauseaGastrointestinal disorders | 2/268 | 5/249 |
| PneumoniaInfections and infestations | 4/268 | 5/249 |
| Neutropenic colitisGastrointestinal disorders | 5/268 | 0/249 |
| VomitingGastrointestinal disorders | 5/268 | 2/249 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/268 | 4/249 |
| ColitisGastrointestinal disorders | 4/268 | 1/249 |
| Event | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 184/268 | 134/249 |
| DiarrhoeaGastrointestinal disorders | 163/268 | 57/249 |
| NauseaGastrointestinal disorders | 157/268 | 86/249 |
| AlopeciaSkin and subcutaneous tissue disorders | 128/268 | 46/249 |
| FatigueGeneral disorders | 106/268 | 81/249 |
| AnaemiaBlood and lymphatic system disorders | 97/268 | 68/249 |
| ConstipationGastrointestinal disorders | 93/268 | 61/249 |
| VomitingGastrointestinal disorders | 63/268 | 39/249 |
| AstheniaGeneral disorders | 62/268 | 49/249 |
| Decreased appetiteMetabolism and nutrition disorders | 57/268 | 52/249 |
The Intent-to-Treat (ITT) Population included all participants who were randomized, regardless of whether they received study treatment or not.
| Age, Categorical(Participants) | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) | Total~(N=543) |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 199 | 204 | 403 |
| >=65 years | 73 | 67 | 140 |
| Age, Continuous(years) | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) | Total~(N=543) |
|---|---|---|---|
| Mean | 57 ± 11.5 | 56 ± 10.4 | 56 ± 11.0 |
| Sex: Female, Male(Participants) | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) | Total~(N=543) |
|---|---|---|---|
| Female | 270 | 268 | 538 |
| Male | 2 | 3 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) | Total~(N=543) |
|---|---|---|---|
| Hispanic or Latino | 6 | 12 | 18 |
| Not Hispanic or Latino | 222 | 204 | 426 |
| Unknown or Not Reported | 44 | 55 | 99 |
| Race/Ethnicity, Customized(Participants) | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) | Total~(N=543) |
|---|---|---|---|
| Race — White | 184 | 178 | 362 |
| Race — Unknown or Not Reported | 69 | 70 | 139 |
| Race — Black or African American | 8 | 13 | 21 |
| Race — Asian | 11 | 5 | 16 |
| Race — Other or More Than One Race | 0 | 4 | 4 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Sacituzumab Govitecan | Treatment of Physician's Choice (TPC) | Total~(N=543) |
|---|---|---|---|
| United States | 115 | 113 | 228 |
| France | 64 | 73 | 137 |
| Spain | 35 | 34 | 69 |
| Germany | 20 | 26 | 46 |
| Belgium | 16 | 9 | 25 |
| Italy | 9 | 6 | 15 |
| United Kingdom | 7 | 7 | 14 |
| Netherlands | 6 | 2 | 8 |
| Canada | 0 | 1 | 1 |
Showing the first 100 of 113 sites across 9 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from May 2019 to primary completion in Oct 2023, 53 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 53 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sacituzumab govitecan